11201807538P

Text of the abstract

The present invention relates to CRISPR/Cpf1-related compositions and methods for treatment of cancer. The method involves the use of CRISPR/Cpf1 system to modify T cells by targeting a gene selected from the group consisting of FAS, BID, CTLA4, PDCD1, CBLB, PTPN6, B2M, TRAC, and TRBC genes.